AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
05 Feb 2019 07:00 AM
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 03:00 PM
RNS
Total Voting Rights
01 Feb 2019 01:17 PM
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 02:00 PM
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 01:00 PM
RNS
AstraZeneca announces organisational changes
02 Jan 2019 03:00 PM
RNS
Total Voting Rights
20 Dec 2018 01:47 PM
RNS
Bevespi Aerosphere approved in the EU for COPD
20 Dec 2018 07:05 AM
RNS
Lynparza meets primary endpoint in SOLO-3 trial
20 Dec 2018 07:00 AM
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 06:31 PM
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 09:09 AM
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 07:00 AM
RNS
Directorate Change
07 Dec 2018 07:00 AM
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 07:00 AM
RNS
Divestment of rights to Covis completed
04 Dec 2018 03:00 PM
RNS
Director/PDMR Shareholding
03 Dec 2018 04:00 PM
RNS
Block listing Interim Review
03 Dec 2018 04:00 PM
RNS
Total Voting Rights
03 Dec 2018 07:00 AM
RNS
Grünenthal Agreement for Nexium, Vimovo Completed
26 Nov 2018 07:00 AM
RNS
US FDA grants Fasenra ODD for EGPA
16 Nov 2018 07:00 AM
RNS
AstraZeneca provides update on Phase III MYSTIC
13 Nov 2018 07:00 AM
RNS
AstraZeneca to divest US Synagis rights to Sobi
12 Nov 2018 07:05 AM
RNS
US FDA accepts regulatory submission for Lynparza
12 Nov 2018 07:00 AM
RNS
Farxiga significantly reduced hospitalisation for
08 Nov 2018 07:00 AM
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 07:00 AM
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 03:00 PM
RNS
Total Voting Rights
31 Oct 2018 09:45 AM
RNS
Additional financial information-Grünenthal deal
30 Oct 2018 07:00 AM
RNS
Grünenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 07:00 AM
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 07:00 AM
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 01:09 PM
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 07:00 AM
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 03:00 PM
RNS
Total Voting Rights
01 Oct 2018 07:00 AM
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 04:00 PM
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 01:15 PM
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 04:10 PM
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
24 Sep 2018 07:00 AM
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 07:00 AM
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 07:00 AM
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 07:00 AM
RNS
Directorate Change
03 Sep 2018 03:00 PM
RNS
Total Voting Rights
31 Aug 2018 07:00 AM
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 07:00 AM
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 07:00 AM
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 07:00 AM
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 07:00 AM
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 03:00 PM
RNS
Total Voting Rights
27 Jul 2018 02:00 PM
RNS
CHMP recommends Imfinzi for Stage III nsclc

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100